Dr. Lan Luo, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 37
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 2,572
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
FL license ME106023
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Tampa Tampa, FL
- Adventhealth Ocala Ocala, FL
- Marion Communtiy Hospital Ocala, FL
Medical groups
- Ocala Heart Clinic II LLC (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 2,572
- Services billed
- 17,215
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 5,903 | 1,817 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 1,538 | 1,503 |
| Injection, regadenoson, 0.1 mg | 1,069 | 268 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 976 | 486 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 960 | 301 |
| Ultrasound of both sides of head and neck blood flow | 945 | 932 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 708 | 573 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 509 | 508 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 488 | 488 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 457 | 183 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Ocala, FL | 1,754 |
| Losartan Potassium Other prescribers in Ocala, FL | 1,662 |
| Metoprolol Tartrate Other prescribers in Ocala, FL | 1,633 |
| Metoprolol Succinate Other prescribers in Ocala, FL | 1,576 |
| Carvedilol Other prescribers in Ocala, FL | 1,418 |
| Eliquis (apixaban) Other prescribers in Ocala, FL | 1,411 |
| Amlodipine Besylate Other prescribers in Ocala, FL | 1,345 |
| Atorvastatin Calcium Other prescribers in Ocala, FL | 1,073 |
| Furosemide Other prescribers in Ocala, FL | 932 |
| Ezetimibe Other prescribers in Ocala, FL | 891 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 47 payments worth $1,081 in total to this clinician.
| Food and Beverage | $1,081 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 7 companies. The companies reported $763,175 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly…
Amgen Inc. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim International GmbH - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascula…
Novartis Pharmaceuticals Corporation - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a)
Novartis Pharmaceuticals Corporation - Study name not reported
Ionis Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.